Overview

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Mologen AG